NAT2 slow acetylator is a confirmed risk of anti-tuberculosis drug-induced liver injury (ATDILI). However, NAT2 ultra-slow acetylators, a new refinement among NAT2 slow acetylators, have been recently proposed. The patients with NAT2 genotypes of *6A/*6A, *6A/*7B and *7B/*7B are referred to in this group. We aim to prove an association of the NAT2 ultra-slow acetylators with the risk of ATDILI. Systematic review and meta-analysis were performed based on each NAT2 genotype and risk of ATDILI cases and also new classification of the ultra-slow acetylators up to 31 October 2016. Meta-analysis of 18 studies with 822 ATDILI cases and 4630 controls was carried out in the RevMan software, version 5.3 with fixed-effect (low heterogeneity) and random effect (moderate to high heterogeneity) methods. The strong associations between each NAT2 slow acetylator genotypes and ATDILI were confirmed in meta-analysis except for NAT2*5B/*5B [odds ratio (OR): 1.69; 95% confidence interval (CI): 0.96-2.95; P=0.0679]. The NAT2 ultra-slow acetylators contribute to higher risk of ATDILI (OR: 3.60; 95% CI: 2.30-5.63; P=1.76E-08) than all NAT2 slow acetylators (OR: 2.80; 95% CI: 2.20-3.57; P=5.73E-18) as well as fast acetylators. Additional in-vitro study using isoniazid as a substrate supports the existence of ultra-slow acetylator alleles (NAT2*6A and NAT2*7B). This is the first meta-analysis of NAT2 and the risk of ATDILI at the genotypic level. The result demonstrated that NAT2 ultra-slow acetylator genotypes will have the most effect on the increased risk of ATDILI.
Meningitis infection is one of the major threats during Hajj season in Mecca. Meningitis vaccines are available, but their uses are limited in some countries du...
Dengue is an infectious disease caused by dengue virus (DENV) and transmitted between human hosts by mosquitoes. Recently, Indonesia was listed as a country wit...
11 July 2025 in Pharmacology Research & Perspectives
Pharmacogenomics (PGx) is a crucial part of precision medicine; however, its integration into clinical practice has been slow, primarily due to knowledge gaps regarding pharmacogenomics among healthcare professionals (HCPs). Pharmacogenomics education is considered the most influential barrier to the successful implementation of PGx. In the Middle East and North Africa (MENA) region, several studies have highlighted the lack of PGx education among students and HCPs. This scoping review aims to provide an overview of the existing literature on how PGx is delivered in the curricula and its impact on knowledge acquisition among students and HCPs in the MENA region. A database search of PubMed, Embase, and CINAHL was conducted up to June 2023. Outcomes included PGx education availability, curriculum placement, mode of delivery, and knowledge level. Seven cross‐sectional studies were identified (2014–2023), with 57% from the Gulf region. PGx education is mostly taught to undergraduates (71%) through didactic lectures (100%), with only a few studies reporting a standalone course (29%). Participants demonstrated low (43%) to moderate (43%) knowledge levels, assessed using objective scales or subjective self‐assessment after completion of the course. Reported barriers to implementing PGx education included knowledge gaps, economic constraints, and system sustainability. PGx education in the MENA region is delivered mainly as an integrated course in professional programs including pharmacy and medicine, and the overall knowledge level was low to moderate. Future research could focus on providing more detailed reporting of the PGx educational landscape, developing standardized assessment tools, and evaluating actual knowledge acquisition among different professions.
30 September 2016 in International Journal of Biomass and Renewables